BPN14770
BPN14770 is a pharmaceutical drug with 10 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 9 completed trials
Phase Distribution
Phase Distribution
7
Early Stage
3
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
9 of 9 finished
0.0%
0 ended early
1
trials recruiting
10
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls
Study of BPN14770 in Participants With Severe Renal Impairment and Healthy Controls
Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])
A Study to Assess the Effects of BPN14770 on Rosuvastatin
Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects
Clinical Trials (10)
Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls
Study of BPN14770 in Participants With Severe Renal Impairment and Healthy Controls
Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])
A Study to Assess the Effects of BPN14770 on Rosuvastatin
Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects
A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome
Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D)
Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers
BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects
A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects
All 10 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 10